Answer
Yes, hepatitis B reactivation can occur in chronic carriers receiving Glivec (imatinib), with some cases after BCR-ABL tyrosine kinase inhibitors resulting in acute liver failure or fulminant hepatitis leading to liver transplantation or death.
Sources for this answer
- GLIVEC film-coated tabletsNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 41Document updated
Sources checked